SESSION VIII: T-CELL LYMPHOMA

Session Chairs: Neha Mehta-Shah and Alison Moskowitz

A Clinically Relevant Overview of the Current PTCL Classification | Ahmet Dogan, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Optimizing Frontline Treatment for PTCL | Neha Mehta-Shah, MD, MSCI | Washington University School of Medicine, St. Louis, Missouri, USA

Emerging Novel Therapies for T-Cell Lymphoma | Owen A O’Connor, MD, PhD | UVA Comprehensive Cancer Center, Charlottesville, Virginia, USA

Practical Approach to Management of CTCL | Alison J Moskowitz, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Diagnosis and Treatment of PTCL in South America | Carlos Chiattone, MD, PhD | Santa Casa Medicine School, São Paulo, Brazil

Oral Abstract | TCL-394: Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial | Stefan K Barta, MD, MS | University of Pennsylvania, Philadelphia, Pennsylvania, USA